CA2250042A1
(en)
|
1996-03-25 |
1997-10-02 |
Eli Lilly And Company |
Treating pain using a synergistic combination of an atypical antipsychotic and a drug used in treatment of pain
|
US6489341B1
(en)
|
1999-06-02 |
2002-12-03 |
Sepracor Inc. |
Methods for the treatment of neuroleptic and related disorders using sertindole derivatives
|
SI1458888T1
(sl)
*
|
2001-12-10 |
2011-07-29 |
Novartis Ag |
Metode zdravljenja psihoze in shizofrenije na osnovi polimorfizmov gena cntf
|
MXPA05012317A
(es)
*
|
2003-05-16 |
2006-01-30 |
Pfizer Prod Inc |
Combinaciones terapeuticas de agentes antipsicoticos atipicos con agentes moduladores del gaba anticonvulsivos o benzodiazepinas.
|
GB0326148D0
(en)
|
2003-11-10 |
2003-12-17 |
Lilly Co Eli |
Morpholine derivatives
|
AU2004294348A1
(en)
*
|
2003-12-04 |
2005-06-16 |
The Research Foundation Of The City University Of New York |
Clozapine and cocaine effects on dopamine and serotonin release in nucleus accumbens during psychostimulant behavior and withdrawal
|
EP1737473A4
(en)
*
|
2004-04-19 |
2009-08-26 |
Noven Therapeutics Llc |
COMBINATIONS OF LITHIUM AND USES THEREOF
|
MXPA06013163A
(es)
*
|
2004-05-11 |
2007-02-13 |
Pfizer Prod Inc |
Combinacion de antipsicoticos atipicos y antagonistas del receptor 5-ht1b.
|
MY147767A
(en)
*
|
2004-06-16 |
2013-01-31 |
Janssen Pharmaceutica Nv |
Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
|
AR049646A1
(es)
*
|
2004-06-16 |
2006-08-23 |
Janssen Pharmaceutica Nv |
Derivados de sulfamato y sulfamida utiles para el tratamiento de la epilepsia y trastornos relacionados
|
TW200616608A
(en)
*
|
2004-07-09 |
2006-06-01 |
Forest Laboratories |
Memantine as adjunctive treatment to atypical antipsychotics in schizophrenia patients
|
JP4912312B2
(ja)
*
|
2004-08-24 |
2012-04-11 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
抗痙攣薬として有用な新規なベンゾ−縮合ヘテロアリールスルファミド誘導体
|
AU2006249577A1
(en)
*
|
2005-05-20 |
2006-11-30 |
Janssen Pharmaceutica N.V. |
Process for preparation of sulfamide derivatives
|
US20070212412A1
(en)
*
|
2005-09-08 |
2007-09-13 |
H. Lundbeck A/S |
Stable solid formulation of sertindole
|
US20070155823A1
(en)
*
|
2005-12-19 |
2007-07-05 |
Smith-Swintosky Virginia L |
Use of benzo-fused heterocycle sulfamide derivatives as neuroprotective agents
|
US8716231B2
(en)
|
2005-12-19 |
2014-05-06 |
Janssen Pharmaceutica Nv |
Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
|
US8937096B2
(en)
*
|
2005-12-19 |
2015-01-20 |
Janssen Pharmaceutica Nv |
Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
|
US8497298B2
(en)
*
|
2005-12-19 |
2013-07-30 |
Janssen Pharmaceutica Nv |
Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
|
US20070155827A1
(en)
*
|
2005-12-19 |
2007-07-05 |
Smith-Swintosky Virginia L |
Use of benzo-fused heterocycle sulfamide derivatives for the treatment of depression
|
AR058389A1
(es)
*
|
2005-12-19 |
2008-01-30 |
Janssen Pharmaceutica Nv |
Uso de derivados heterociclicos benzo-fusionados de sulfamida para el tratamiento de la obesidad
|
US8691867B2
(en)
*
|
2005-12-19 |
2014-04-08 |
Janssen Pharmaceutica Nv |
Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
|
JP2009537635A
(ja)
*
|
2006-05-19 |
2009-10-29 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
癲癇の処置のための共同−療法
|
TW200821296A
(en)
*
|
2006-06-01 |
2008-05-16 |
Lundbeck & Co As H |
Use of sertindole for the preventive treatment of suicidal behaviour
|
EP2041304B1
(en)
|
2006-06-12 |
2011-09-07 |
Hadasit Medical Research Services & Development Limited |
Rgs2 genotypes associated with extrapyramidal symptoms induced by antipsychotic medication
|
PT2083811T
(pt)
|
2006-11-22 |
2017-01-23 |
Clinical Res Ass Llc |
Métodos de tratamento da síndrome de down, síndrome do x frágil e autismo
|
US20090247617A1
(en)
*
|
2008-03-26 |
2009-10-01 |
Abdel-Magid Ahmed F |
Process for the preparation of benzo-fused heteroaryl sulfamates
|
WO2009128058A1
(en)
|
2008-04-18 |
2009-10-22 |
UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al |
Psycho-pharmaceuticals
|
CA2729056A1
(en)
*
|
2008-06-23 |
2010-01-21 |
Janssen Pharmaceutica Nv |
Crystalline form of (2s)-(-)-n-(6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-sulfamide
|
CA2727573A1
(en)
*
|
2008-06-25 |
2009-12-30 |
Pfizer Inc. |
Diaryl compounds and uses thereof
|
US8815939B2
(en)
*
|
2008-07-22 |
2014-08-26 |
Janssen Pharmaceutica Nv |
Substituted sulfamide derivatives
|
US8252801B1
(en)
|
2009-06-03 |
2012-08-28 |
Abbott Laboratories |
Treatment of schizophrenia and related disorders
|
EP2919788A4
(en)
|
2012-11-14 |
2016-05-25 |
Univ Johns Hopkins |
METHODS AND COMPOSITIONS FOR THE TREATMENT OF SCHIZOPHRENIA
|
EP2968237A4
(en)
|
2013-03-15 |
2016-08-31 |
Univ Johns Hopkins |
METHOD AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTION
|
DK2968220T3
(da)
|
2013-03-15 |
2021-06-14 |
Agenebio Inc |
Fremgangsmåder og sammensætninger til forbedring af kognitiv funktion
|
BR112017025031B1
(pt)
|
2015-05-22 |
2023-03-21 |
Agenebio, Inc |
Composições farmacêuticas de liberação prolongada de levetiracetam
|